Emerald Advisers Inc. PA lifted its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 40.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 569,416 shares of the company’s stock after purchasing an additional 162,990 shares during the period. Emerald Advisers Inc. PA owned about 3.06% of Reata Pharmaceuticals worth $17,709,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RETA. FMR LLC increased its stake in Reata Pharmaceuticals by 74.4% during the second quarter. FMR LLC now owns 414,491 shares of the company’s stock valued at $13,114,000 after purchasing an additional 176,885 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Reata Pharmaceuticals by 109.6% during the second quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock worth $9,350,000 after acquiring an additional 154,515 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in Reata Pharmaceuticals by 7.0% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 293,927 shares of the company’s stock valued at $9,300,000 after buying an additional 19,235 shares in the last quarter. JPMorgan Chase & Co. grew its position in Reata Pharmaceuticals by 78.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 232,562 shares of the company’s stock valued at $7,359,000 after buying an additional 101,969 shares in the last quarter. Finally, State Street Corp grew its position in Reata Pharmaceuticals by 4.9% in the 2nd quarter. State Street Corp now owns 108,212 shares of the company’s stock valued at $3,422,000 after buying an additional 5,094 shares in the last quarter. 15.68% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on RETA shares. Citigroup Inc. reissued a “buy” rating and issued a $87.00 price target (up from $39.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Leerink Swann started coverage on shares of Reata Pharmaceuticals in a report on Wednesday, September 13th. They issued an “outperform” rating and a $43.00 price target for the company. Jefferies Group LLC started coverage on shares of Reata Pharmaceuticals in a report on Wednesday, August 30th. They issued a “buy” rating and a $44.00 price target for the company. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $61.00 price target (up from $55.00) on shares of Reata Pharmaceuticals in a report on Wednesday, July 26th. Finally, Robert W. Baird reissued a “buy” rating and issued a $47.00 price target on shares of Reata Pharmaceuticals in a report on Tuesday, October 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $54.71.

ILLEGAL ACTIVITY NOTICE: “Emerald Advisers Inc. PA Acquires 162,990 Shares of Reata Pharmaceuticals, Inc. (RETA)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.watchlistnews.com/emerald-advisers-inc-pa-acquires-162990-shares-of-reata-pharmaceuticals-inc-reta/1675726.html.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.